Glucocorticoid therapy for acute respiratory distress syndrome:Currentconcepts  

作　　者：Yuanrui Zhao Zhun Yao Song Xu Lan Yao Zhui Yu 

机构地区：[1]Department of Critical Care Medicine,Renmin Hospital of Wuhan University,Wuhan,Hubei,China

出　　处：《Journal of Intensive Medicine》2024年第4期417-432,共16页重症医学（英文）

摘　　要：Acute respiratory distress syndrome(ARDS),a fatal critical disease,is induced by various insults.ARDS represents a major global public health burden,and the management of ARDS continues to challenge healthcaresystems globally,especially during the pandemic of the coronavirus disease 2019(COVID-19).There remains noconfirmed specific pharmacotherapy for ARDS,despite advances in understanding its pathophysiology.Debatecontinues about the potential role of glucocorticoids(GCs)as a promising ARDS clinical therapy.Questions regarding GC agent,dose,and duration in patients with ARDS need to be answered,because of substantial variationsin GC administration regimens across studies.ARDS heterogeneity likely affects the therapeutic actions of exogenous GCs.This review includes progress in determining the GC mechanisms of action and clinical applications inARDS,especially during the COVID-19 pandemic.

关 键 词：Acute respiratory distress syndrome GLUCOCORTICOIDS STEROIDS COVID-19 Clinical trials HETEROGENEITY 

分 类 号：R56[医药卫生—呼吸系统]